46 / 96
46
Informaciones
Psiquiátricas
2019 - n.º
236
zophrenia and schizoaffective disorder.
Psychiatry Res. 2002;111:11–20.
29. Misra M, Papakostas GI, Klibanski A.
Effects of psychiatric disorders and
psychotropic medications on prolactin
and bone metabolism. J Clin Psychiatry
2004;65:1607-1618.
30. Bhuvaneswar CG, Baldessarini RJ,
Harsh VL, Alpert JE. Adverse endocrine
and metabolic effects of psychotropic
drugs: Selective clinical review. CNS
Drugs 2009;23:1003-1021.
31. O’Keane V. Antipsychotic-induced
hyperprolactinaemia, hypogonadism
and osteoporosis in the treatment of
schizophrenia. J Psychopharmacol.
2008;22 2 Suppl:70–5.
32. Howard L, Kirkwood G, Leese M. Risk of
hip fracture in patients with a his-
tory of schizophrenia. Br J Psychiatry.
2007;190:129–34.
33. Montejo ÁL, Arango C, Bernardo M,
Carrasco JL, Crespo-Facorro B, Cruz JJ,
Del Pino J, García Escudero MA, García
Rizo C, González-Pinto A, Hernández
AI, Martín Carrasco M, Mayoral Cle-
ries F, Mayoral van Son J, Mories MT,
Pachiarotti I, Ros S, Vieta E. Spanish
consensus on the risks and detection
of antipsychotic drug-related hyperpro-
lactinaemia. Rev Psiquiatr Salud Ment.
2016 Jul-Sep;9(3):158-73. Spanish
34. Citrome L. Current guidelines and their
recommendations for prolactin monito-
ring in psychosis. J Psychopharmacol.
2008;22 2 Suppl:90–7.
35. Peveler RC, Branford D, Citrome L,
Fitzgerald P, Harvey PW, Holt RI,
et al. Antipsychotics and hyperpro-
lactinaemia: Clinical recommenda-
tions. J Psychopharmacol. 2008;22 2
Suppl:98–103.)
36. Bobes-Garcia J, Saiz-Ruiz J, Bernardo-
Arroyo M, Caballero-Martinez F, Gila-
berte-Asin I, Ciudad-Herrera A. Delphi
consensus on the physical health of
patients with schizophrenia: Evaluation
of the recommendations of the Spanish
Societies of Psychiatry and Biological
Psychiatry by a panel of experts. Actas
Esp Psiquiatr. 2012;40:114–28.
37. Organización Mundial de la Salud. Guía
de la clasificación CIE-10.Madrid, Edi-
torial Médica Panamericana; 2000.
38. Valiquette G: Risperidone in children
with autism and serious behavioral
problems. N Engl J Med 347:1890–1891
(autor reply 1890–1891), 2002.
39. Pappagallo M, Silva R. The effect of
atypical antipsychotic agents on pro-
lactin levels in children and adoles-
cents. J Child Adoles Psychopharmacol
14:359–371, 2004.
40. Hellings JA, Zarcone JR, Valdovinos
MG, Reese RM, Gaughan E, Schroeder
SR. Risperidone-Induced Prolactin
Elevation in a Prospective Study of
Children, Adolescents, and Adults with
Mental Retardation and Pervasive De-
velopmental Disorders. J Child Adoles
Psychopharmacol 2005;15(6):885-892.
41. Frighi V, Stephenson MT, Morovat A,
Jolley IE, Trivella M, Dudley CA, et
E. González-Pablos / J.A. López-Villalobos / J.M. Valles-de la Calle / P. Paulino-Matos / F.J. García-Sánchez /
N. Miguel de Diego / I. Esquer-Terrazas / C. Martín-Lorenzo